1 Amount and intensity of physical activity and risk of incident cancer in the UK Biobank

- 2 Ms. Alaina H. Shreves, M.S.¹⁻³; Dr. Scott R. Small, DPhil.^{1,2,4}; Dr. Rosemary Walmsley^{1,2}; DPhil;
- 3 Dr. Shing Chan, DPhil^{1,2}; Dr. Pedro F. Saint-Maurice, Ph.D.^{3,6}; Dr. Steven C. Moore, Ph.D.³; Dr.
- 4 Keren Papier, Ph.D.⁵; Dr. Kezia Gaitskell, D.Phil.⁵; Dr. Ruth C. Travis, DPhil⁵; Dr. Charles E.
- 5 Matthews, Ph.D.³; Dr. Aiden Doherty, Ph.D.^{1,2}

6 **Affiliations:**

- ⁷ ¹ Nuffield Department of Population Health, University of Oxford, UK.
- 8 ² Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of
- 9 Oxford, Oxford, UK.
- ³ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of
- 11 Health, Bethesda, MD, USA.
- ⁴ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University
- 13 of Oxford, Oxford, UK.
- ⁵ Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford,
- 15 Oxford, UK.
- ⁶ Breast Cancer Unit, Champalimaud Foundation, Lisbon, Portugal.
- 17

18 **Corresponding author:**

- 19 Aiden Doherty, Ph.D.
- 20 Professor of Biomedical Informatics
- 21 University of Oxford
- 22 Nuffield Department of Population Health
- 23 Big Data Institute, Old Road Campus
- 24 Oxford, UK OX3 7LF
- 25 Email: <u>aiden.doherty@ndph.ox.ac.uk</u>
- 26
- 27 Manuscript word count: 2 989 words

28 KEY POINTS

- Question: What insights can we gain about the relationships between total daily activity, step
 counts, and activity intensity on cancer risk using accelerometer data?
- Findings: In an analysis of 86 556 individuals from the UK Biobank who provided a week of accelerometer-based activity data, higher levels of total physical activity, reducing sedentary time in favour of light or moderate-vigorous intensity activities, and higher daily step counts were associated with a lower risk of certain cancers.
- 35 Meaning: For less active adults, increasing activity time and accumulating more daily steps may
 36 be practical interventions for lowering the risk of some cancers.

37 ABSTRACT

38 Importance: The influence of total daily and light intensity activity on cancer risk remains 39 unclear, as most existing knowledge is drawn from studies relying on self-reported leisure-time 40 activities of moderate-vigorous intensity.

41 **Objective:** To investigate associations between total daily activity, including step counts, and
42 activity intensity on incident cancer risk.

43 Design, Setting, and Participants: Prospective analysis of cancer-free UK Biobank participants
44 who wore accelerometers for 7-days (between 2013-2015), followed for cancer incidence through
45 national registries (mean follow-up 5.8 years (SD=1.3)).

46 Exposures: Time-series machine learning models derived daily total activity (average
47 acceleration), behaviour time, step counts, and peak 30-minute cadence from wrist-based
48 accelerometer data.

49 Main Outcomes and Measures: A composite cancer outcome of 13 cancers previously associated 50 with low physical activity (bladder, breast, colon, endometrial, oesophageal adenocarcinoma, 51 gastric cardia, head and neck, kidney, liver, lung, myeloid leukaemia, myeloma, and rectum) based 52 on previous studies of self-reported activity. Cox proportional hazards regression models estimated 53 hazard ratios (HR) and 95% confidence intervals (CI), adjusted for age, sex, ethnicity, smoking, 54 alcohol, education, Townsend Deprivation Index, and reproductive factors. Associations of 55 reducing sedentary time in favour of increased light and moderate-vigorous activity were 56 examined using compositional data analyses.

57 **Results:** Among 86 556 participants (mean age 62.0 years (SD=7.9) at accelerometer assessment), 58 2 669 cancers occurred. Higher total physical activity was associated with a lower overall cancer 59 risk (HR_{1SD}=0.85, [95%CI 0.81-0.89]). On average, reallocating one hour/day from sedentary 60 behaviour to moderate-vigorous physical activity was associated with a lower risk (HR=0.92, 61 [0.89-0.95]), as was reallocating one hour/day to light-intensity physical activity (HR=0.94, [0.92-62 0.96]). Compared to individuals taking 5 000 daily steps, those who took 9 000 steps had an 18% 63 lower risk of physical-activity-related cancer (HR=0.82, [0.74-0.90]). We found no significant 64 association with peak 30-minute cadence after adjusting for total steps.

65 Conclusion and Relevance: Higher total daily physical activity and less sedentary time, in favour 66 of both light and moderate-vigorous intensity activity, were associated with a lower risk of certain 67 cancers. For less active adults, increasing step counts by 4 000 daily steps may be a practical public 68 health intervention for lowering the risk of some cancers.

69 **INTRODUCTION**

Epidemiological data indicate that over half of all new cancers in high-income countries could be 70 avoided by modifying lifestyle factors, including addressing physical inactivity.^{1,2} However, 71 72 quantifying the dose-dependent benefits of specific physical activity (PA) behaviours for cancer 73 prevention remains challenging. Many existing studies rely on self-report questionnaires, which 74 emphasize time spent in leisure-time activities of a moderate-vigorous intensity and may have recall errors and reporting biases.^{3,4} Time use data studies suggest that most individuals spend a 75 76 significant amount of time devoted to work and household activities, with the majority of physically active time obtained from light-intensity physical activity (LIPA).^{5–7} Global adherence 77 78 to PA recommendations, which primarily emphasize moderate-vigorous physical activity (MVPA), is generally poor.⁸ Consequently, there is a growing interest in understanding whether 79 80 more accurate measures of MVPA show protective effects for cancer risk and if interventions to 81 increase LIPA could be a valuable disease prevention strategy.

Wearable accelerometer devices provide objective measures of all daily activities, including sedentary and physically active time accumulated at home, work, during transportation, and in leisure-time.⁹ Accelerometer data can also be used to investigate how reallocating time from sedentary behaviour to either LIPA or MVPA could influence disease risk. Existing accelerometermeasured activity studies in cancer have primarily focused on cancer mortality and,^{10–14} to a limited extent, breast cancer risk.^{15,16}

To address these gaps and challenges, we aimed to understand the relationship between total daily
activity and intensity, step counts, and incident cancer risk using a composite outcome of 13 cancer

sites previously associated with low PA in studies of self-reported leisure time activity.¹⁷ As a 90 91 secondary analysis, we assessed the risks for all 13 PA-related cancers individually and, as case 92 numbers allowed, for other site-specific cancers. We also conducted compositional data analyses 93 to explore the impact of reallocating time from sedentary behaviour to LIPA and MVPA. Finally, 94 for potential translation to the clinical and public health settings, we examined the dose-response relationship between step count, stepping intensity, and incident cancer. Step counts are an easily 95 96 understandable metric among the general population and are reported by many consumer wearable 97 devices and fitness trackers.¹⁸

98 METHODS

99 Study population

100 The UK Biobank is a prospective study that enrolled 502 536 adults in England, Scotland, and 101 Wales between 2006-2010.^{19,20} At baseline, participants completed a questionnaire, provided 102 biological data, and consented for linkage to electronic medical records. From June 2013 to 103 December 2015, participants with valid emails were invited to wear an Axivity AX3 wrist-worn 104 accelerometer for 7 days.⁷

105 Accelerometer data processing

106 Accelerometer data were processed using methods described by Doherty ("accelerometer", 107 v7.1.0).²¹ Total physical activity (PA) was calculated as the mean vector magnitude per epoch to 108 derive an overall mean per day acceleration in milligravity (mg) units. This metric reflects the 109 activity duration and intensity and has been validated against doubly labelled water.²¹

Proportions of time spent across sleep, sedentary behaviour (SB), light-intensity physical activity (LIPA), and moderate-vigorous physical activity (MVPA) per day, were calculated using random forest and hidden Markov model machine-learning methods.⁷ Missing time due to non-wear was imputed by averaging the behaviour in the corresponding times across all valid days.⁷

Step counts were calculated using a hybrid self-supervised learning model trained on ground truth free-living stepping data ("stepcount", v3.1.1).²² Daily step count was reported as the median number of daily steps during the seven-day measurement period. Peak 30-minute cadence was calculated as the mean of the 30 highest daily cadence values, averaged across all days.²³ Further processing details are described in eTable 1.

119 **Outcome ascertainment**

The main outcome was a composite cancer outcome of 13 sites previously found to be associated with low PA (bladder, breast, colon, endometrial, oesophageal adenocarcinoma, gastric cardia, head and neck, kidney, liver, lung, myeloid leukaemia, myeloma, and rectal).¹⁷ Cancers were obtained by the UK Biobank through the National Health Service (NHS) Digital for participants from England and Wales and the NHS Central Register for participants from Scotland (details in eTable 2).²⁴ In secondary analyses, we assessed the risks for cancers not previously related to PA with at least 100 cases (eTable 3).

127 Analytic sample

Raw accelerometer data from 103 614 participants were processed, excluding study withdrawals.
We further excluded participants with device calibration or data reading errors (>1% of values

outside +/-8g range), inadequate wear time (<72 hours), unreasonably high average acceleration
(>100 mg), and lacking steps data.{Citation} Individuals with cancer (excluding C44: nonmelanoma skin cancer) before accelerometer wear and missing healthcare linkages or covariate
data, were also excluded. The final analysis included 86 556 participants (eFigure 1).

134 Statistical analysis

135 Cox proportional hazards regression models estimated adjusted Hazard ratios (HRs) with 95%

136 confidence intervals for a one standard deviation (SD) increase in total activity and incident cancer.

137 We also assessed risks across quintiles of physical activity.

Attained age was the underlying time scale. Individuals who were cancer-free during follow-up
were censored at their date of death or at the end of the follow-up period (31 December 2020,
England; 31 December 2016, Wales; 30 November 2021 Scotland).

141 Multivariable models adjusted for sex (male, female), ethnicity (White, non-White), smoking 142 status (never, previous, current unknown cigarettes/day, current <15 cigarettes/day, current \geq 15 143 cigarettes/day), alcohol consumption (never, <3 times per week), ≥ 3 times per week), education 144 (school leaver, further education, higher education), and deprivation based on the Townsend 145 Deprivation Index (TDI) (quintiles ranging from least deprived to most deprived, based on the 146 2011 UK census).²⁵ Female-specific models were further adjusted for oral contraception ever use 147 (no, yes, missing), hormone replacement therapy ever use (no, yes, missing), menopausal status 148 (no, yes, missing/unknown), and parity (0, 1-2, 3+, missing). Covariate data were provided by 149 participants at the UK Biobank baseline assessment and were chosen a priori based on existing

studies (Details in eTable 1). No violations of the proportional hazards assumption were observedfor the exposures using Schoenfeld residuals.

152 Compositional data analyses, using the "epicoda" package, modelled associations between the relative time spent in SB, LIPA, MVPA, and sleep and cancer risk.⁷ First, we calculated the 153 154 estimated HR associated with reallocating time to one behaviour from all other proportionally (e.g., reallocating one hour/day to LIPA from all other behaviours proportionally). ⁷ Second, we 155 156 estimated HRs for specific pairwise reallocations of time between behaviours (e.g., reallocating 157 one hour/day from SB to LIPA, holding sleep and MVPA constant). For all compositional 158 analyses, the estimated hazard ratios were relative to the mean behaviour composition among 159 included participants for a hypothetical average participant.

Finally, we used restricted cubic splines to assess the relationship between step count and cancer incidence using a reference point at the 10th percentile and knots positioned at the 5th, 50th, and 90th percentiles. We employed *P*-values for linear trends to estimate significance of the overall association. Multivariable models were further adjusted for daily step count.

We conducted several sensitivity analyses, including adjustment for body mass index (<25, 25-30, and 30+ kilograms/meters²) as measured at the assessment centre and dietary factors (fresh fruits and vegetable consumption (<3, 3–4.9, 5–7.9, or 8+ servings/day, missing); red and processed meat consumption (<1, 1–2.9, 3–4.9, or 5+ times/week, missing)). Two subgroup analyses were conducted, one among males and females, and the other among never smokers. To assess the potential influence of reverse causality, we repeated the analyses after excluding the first two years of follow-up. Statistical analyses were performed May-November 2023 using R (v4.2.2; R

Foundation for Statistical Computing). Two-sided P values of <0.05 was considered statistically
significant.

173 Consent

Participants in the UK Biobank provided written informed consent. The study was approved by
the National Information Governance Board for Health and Social Care and the National Health
Service North West Multicentre Research Ethics Committee (06/MRE08/65). We adhered to the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guidelines (eTable 4).²⁶

179 **RESULTS**

180 Among 86 556 participants, the mean age at accelerometer assessment was 62.0 years (SD=7.9).

181 The majority were female (56%), identified as White (97%), and fell within the least deprived

182 quintile of the Townsend Deprivation Index (50%) (Table 1). Throughout a mean follow-up of 5.8

183 years (SD=1.3; 504 557 person-years), 2 669 physical activity (PA)-related cancers accrued, with

184 breast among females (n=995) being the most common (details in eTable 3).

185 Total daily PA and cancer incidence

Higher total PA was associated with a lower risk of PA-related cancer (hazard ratio (HR) per 1 SD
(8.3 milligravity (mg) units), 0.85 [95% confidence interval (CI) 0.81-0.89]) in the multivariableadjusted models (Figure 1; eTable 5). Similar associations were found in models assessing
quintiles of total PA (eTable 6).

190 To explore which cancers contributed to this result, we also examined associations for individual 191 cancer sites (Figure 1; eTable 5). With higher daily PA, we observed a significantly lower risk for 192 seven types; gastric cardia (HR_{1SD}=0.39, [95% CI 0.22-0.70]), liver (HR_{1SD}=0.65, [0.47-0.90]), 193 bladder ($HR_{1SD}=0.69$, [0.55-0.87]), lung ($HR_{1SD}=0.75$, [0.65-0.86]), endometrial ($HR_{1SD}=0.78$, 194 [0.65-0.93]), colon (HR_{1SD}=0.84, [0.75-0.95]), and breast cancers (HR_{1SD}=0.91, [0.85-0.97]). 195 There were also suggestive associations (HR < 0.9) for three cancers; oesophageal adenocarcinoma 196 (HR_{1SD}=0.89, [0.68-1.16]), kidney (HR_{1SD}=0.86, [0.71-1.04]), and head and neck cancers 197 (HR_{1SD}=0.84, [0.66-1.07]). Similar associations were found in models assessing quintiles of total 198 PA (eTable 6).

In secondary analysis of non-PA-related cancer sites, we observed no protective association with prostate cancer, an inverse association with non-Hodgkin lymphoma ($HR_{1SD}=0.85$, [0.75-0.97]), and suggestive inverse associations for melanoma ($HR_{1SD}=0.89$, [0.79-1.01]) and pancreatic cancers ($HR_{1SD}=0.86$ [0.71-1.04]).

203 Compositional data analysis

First, we estimated the risks associated with each behaviour individually by reallocating time to one behaviour from all others proportionally for an average individual (eFigure 2). Reallocating one hour/day to LIPA from all other behaviours was associated with a 5% lower risk of PA-related cancer (HR=0.95, [0.93-0.97]) in multivariable-adjusted models. Reallocating one hour/day to MVPA from other behaviours was associated with a 6% lower cancer risk (HR=0.93, [0.90-0.97]). Reallocating one hour/day to sedentary behaviour (SB) was associated with a significantly higher

210 cancer risk (HR=1.03, [1.01-1.06]), but reallocating one hour/day to sleep was not (HR=1.01,
211 [0.98-1.05]).

Next, we estimated the risks associated with specific pairwise reallocations of time between behaviours (Figure 2; eTable 7). For an average participant, reallocating one hour/day from SB to overall physical activity (LIPA + MVPA) was associated with a 7% lower risk (HR=0.93, [0.91-0.95]) in the multivariable-adjusted model. Reallocating one hour/day from SB to MVPA alone was associated with an 8% lower cancer risk (HR=0.92, [0.89-0.95]), and reallocating one hour/day from SB to LIPA was associated with a 6% lower risk (HR=0.94, [0.92-0.96]).

218 Step counts and cancer incidence

Higher daily step counts were associated with a lower risk of PA-related cancers (*P* for trend \leq 0.001) after multivariable adjustments (eTable 8; Figure 3). Compared to individuals who took 5 000 daily steps (10th percentile, reference), individuals who took 9 000 daily steps had an 18% lower risk (HR=0.82, [0.74-0.90]), while those who took 13 000 steps had a 23% lower risk (HR=0.77, [0.69-0.86]). Individuals taking fewer than 5 000 steps had a higher risk.

Higher step intensity (peak 30-minute cadence) was associated with a lower risk of PA-related cancer prior to adjustment for total step counts (Table 2). Compared to individuals who took 70 steps/minute (10^{th} percentile, reference), individuals who took 120 steps/minute had a lower cancer risk before (HR=0.72, [0.59-0.89]), but not after adjusting for total daily steps (HR=0.88, [0.69-1.14], *P* for trend=0.05).

229 Sensitivity analyses

Associations for total PA and cancer risk were slightly attenuated after adjusting for body mass index (BMI) in models per 1-SD of total activity (eTable 5), but the direction between the quintiles was consistent (eTable 6). BMI adjustment did not substantially alter results from the compositional analyses (eFigure 3; eTable 7) or the spline models for step count (eTable 8), nor did adjusting for dietary factors (eTables 5-8, eFigure 4).

235 Sex-specific models of 1-SD differences in total PA showed that patterns of association for cancer 236 risk were similar among males and females for most cancer sites (eTables 9-10), as were findings 237 from the compositional data analysis (eFigure 5). Protective associations were observed for step 238 count and PA-related cancer risk in sex-specific models (eTable 11; Figure 3). Analyses conducted 239 among never smokers were similar to our primary analysis (eTable 12; eFigure 6). After removing 240 the first two years of follow-up, higher activity quintiles demonstrated protective associations for 241 cancer risk, but the impact was more attenuated in lower activity categories (eTable 13; eFigure 242 7).

243 **DISCUSSION**

In this prospective analysis, higher total daily physical activity (PA) measured by accelerometers was associated with a composite of 13 cancers previously shown to be associated with PA in studies of self-reported leisure time activity.¹⁷ We also observed lower risks for 7 of these 13 cancers. Additionally, we found protective associations for minimizing sedentary time in favour of engaging in light intensity physical activity (LIPA) or moderate-vigorous physical activity (MVPA). Compared with individuals who took 5 000 steps per day, those who took 9 000 daily steps had an 18% lower risk of incident PA-related cancer. A weaker suggestive association with

higher step intensity was observed, but results were not significant after adjusting for total stepcount.

253 Results from our compositional data analysis are novel and suggest that less sedentary time in favour of LIPA or MVPA was associated with a lower risk of certain cancers. These findings align 254 255 with previous studies indicating that sedentary behaviour may be associated with chronic disease risk factors and cancer development and progression.^{27–29} Notably, our finding that any intensity 256 257 of PA was beneficial contrasts with findings from cardiovascular disease research, where intensity plays a more pivotal role in determining health benefits.^{7,27} A study by Stamatakis found that short 258 259 bursts of vigorous intensity PA were associated with a lower risk of PA-related cancer among nonexercising adults.³⁰ Our findings suggests that efforts to decrease sedentary behaviour in favour of 260 261 engaging in LIPA or MVPA activities, such as allocating more time to casual walking, household 262 chores, home repairs, and gardening could also support cancer prevention efforts and might be 263 feasible to incorporate into everyday routines. Further, our study was not limited to non-exercisers, 264 which enhances the applicability of our findings.

Walking, a highly accessible and popular form of PA, is often considered an ideal exercise intervention due to its simplicity to track and minimal adverse effects.³¹ Our findings show that higher steps counts were associated with a lower risk for PA-related cancers. In terms of step intensity, we found a weaker but non-significant association after adjusting for total step count. These findings align with our compositional model results for total PA, which suggested that LIPA and MVPA were beneficial for cancer risk. Together, this suggests that walking at any pace may provide health benefits with respect to cancer incidence.

272 Our study adds new information to a limited literature base on the association between total daily PA and incident cancers.¹¹ Previous research in the UK Biobank cohort reported protective 273 274 associations for self-reported PA and cancer, and we extend these findings for many site-specific cancers.^{28,32} Our findings align with other studies using accelerometer data that found physical 275 activity may play a role in the prevention of PA-related cancers among older women³³ and for 276 incident breast cancer.^{15,16} In addition to finding lower risk for 7 of the 13 PA-related cancers 277 278 identified by Moore and colleagues,¹⁷ we also observed a protective association between total PA 279 and non-Hodgkin lymphoma and suggestive associations for melanoma and pancreatic cancers. 280 This suggests potential areas for future research, especially in samples with larger case counts.

Several hypothesized mechanisms linking higher PA with a lower cancer risk have been proposed. These mechanisms encompass hormonal changes, insulin levels, inflammation, immune function, and oxidative stress.²⁹ Some hypotheses suggest that PA may reduce cancer risk by influencing body weight, but we observed no substantial changes in model estimates after adjusting for body mass index, although measurements here were obtained several years before the accelerometer measurements, potentially introducing imprecise estimates over time.

287 Strengths and limitations

Our study has several strengths, including the use of accelerometer devices in a large and prospective cohort study, which reduces susceptibility to recall and reporting biases compared to most previous studies.^{3,4} Accelerometers captured a wide range of daily behaviours, including both sedentary and physically active activities, as well as step count. Further, we processed the accelerometer data using open-source methods.³⁴ Our sample included a wide age-range (43-78

years at accelerometer wear) of participants, making the cohort mature for analysing more common adult-onset cancers.^{19,35} Our results add to the limited literature on how physical activity impacts cancer risk across different cancer sites. We also employed compositional data analyses to model associations for 24-hour behaviours, rather than just individual behaviour risks. In addition, we controlled for key cancer risk factors and conducted extensive sensitivity analysis to examine major threats to the validity of our findings.

299 This study also had several limitations. The UK Biobank cohort includes middle to early late-aged 300 individuals, potentially leading to underrepresentation of cancers with onset at more advanced 301 ages. Secondly, the study is observational, and we cannot exclude the possibility of unmeasured 302 and residual confounding. Reverse causation is also a possibility, as certain cancers may have been 303 undiagnosed at the time of accelerometer wear and could have reduced daily PA. Nonetheless after 304 removing the first two years of follow-up, we observed only minor attenuations. Future UK 305 Biobank studies with additional follow-up will be required to investigate associations for less 306 common cancers. Furthermore, we had accelerometer data from one period during middle-age; 307 thus, we are also unable to draw conclusions about PA earlier in the life in relation to cancer risk. 308 Finally, the study population drawn from the UK Biobank may not be representative of wider populations.³⁶ However, we believe that the etiological findings are still likely to have broader 309 310 applicability.³⁷

311 Conclusion

Results from this prospective study suggest protective associations between engaging in higher levels of overall daily PA, reducing sedentary time in favour of engaging LIPA or MVPA, and

- 314 increasing daily step counts and cancer risk. These findings underscore the potential health benefits
- 315 of incorporating lower intensity activities into daily life during middle age, alongside promoting
- 316 higher intensity activities in public health initiatives focused on cancer prevention.

317 ACKNOWLEDGEMENTS

318 Author Contributions:

- 319 Shreves had full access to all the data in the study and takes responsibility for the integrity of the
- 320 data and the accuracy of the data analysis.
- 321 Concept and design: Shreves, Travis, Matthews, Doherty.
- 322 Acquisition, analysis, or interpretation of data: Shreves, Small, Walmsley, Saint-Maurice, Papier,
- 323 Travis, Matthews, Doherty.
- 324 Drafting of the manuscript: Shreves, Travis, Matthews, Doherty.
- 325 Critical revision of the manuscript for important intellectual content: All authors.
- 326 Statistical analysis: Shreves.
- 327 Obtained funding: Shreves, Travis, Matthews, Doherty.
- 328 Administrative, technical, or material support: Shreves, Chan, Walmsley, Doherty.
- 329 Supervision: Doherty, Matthews, Travis.

330 **Conflict of Interest Disclosures:**

331 Shreves, Moore, Gaitskell, Travis, and Matthews declare no competing interests.

332 Doherty is supported by Novo Nordisk. Doherty accepted consulting fees from the University of 333 Wisconsin (NIH R01 grant) and Harvard University (NIH R01 grant). Doherty received support 334 for presentations at the International Conference on Soft Computing in Data Science 2021, Korean 335 Society of Cardiology 2020, and Oxford International Study Abroad programme 2023. Doherty 336 received support to attend the 2023 CTSU Joint Annual Collaborators' Meeting, London, 2023 Big 337 Model AI for Drug Design workshop, Abu Dhabi, 2023 Festival of Genomics, London, 2022 338 Industry Symposium on Digital Biomarkers, EMBL-EBI, Cambridge, 2020 ELIXIR 339 Bioinformatics Industry Forum, London, 2020 3rd NYU Biomedical and Biosystems Conference, 340 Abu Dhabi, 2020 Academy of Medical Sciences, UK-Japan Symposium on Data-Driven Health. 341 Doherty is a member of the 2021 Scientific advisory board EU IMI IDEA-FAST. Doherty received 342 a donation from SwissRe to purchase equipment for accelerometer data collection in the China 343 Kadoorie Biobank.

344 Doherty, Walmsley, and Chan have released accelerometer analysis software under an academic
345 use license that could result in commercial entities paying license fees for their use.

346 Funding/Support:

347 Shreves, Saint-Maurice, Moore, and Matthews are supported by the National Institutes of Health's 348 Intramural Research Program. Shreves is also supported by the National Institutes of Health's 349 Oxford Cambridge Scholars Program. Walmsley is supported by HDR UK, an initiative funded 350 by UK Research and Innovation, Department of Health and Social Care (England) and the 351 devolved administrations. Papier is supported by Cancer Research UK (grant number 352 C16077/A29186). Chan is supported Novo Nordisk. Doherty and Small are supported by the

- 353 Wellcome Trust (223100/Z/21/Z). Doherty is also supported by Novo Nordisk, Swiss Re, and the
- 354 British Heart Foundation Centre of Research Excellence (grant number RE/18/3/34214). Travis is
- 355 supported by Cancer Research UK (grant number C8221/A29017).

356 **Role of the Funder/Sponsor:**

- 357 The funders/sponsors had no role in the design of this study, the analysis and interpretation of the
- 358 results, or drafting of the manuscript.

359 **REFERENCES**

- Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates
 of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*. 2021;71(3):209-249. doi:https://doi.org/10.3322/caac.21660
- 363 2. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and
 364 deaths attributable to potentially modifiable risk factors in the United States. *CA Cancer J* 365 *Clin.* 2018;68(1):31-54. doi:10.3322/caac.21440
- Shephard RJ. Limits to the measurement of habitual physical activity by questionnaires.
 Br J Sports Med. 2003;37(3):197-206; discussion 206. doi:10.1136/bjsm.37.3.197
- Sallis JF, Saelens BE. Assessment of physical activity by self-report: status, limitations, and future directions. *Res Q Exerc Sport*. 2000;71 Suppl 2:1-14. doi:10.1080/02701367.2000.11082780
- Tudor-Locke C, Leonardi C, Johnson WD, Katzmarzyk PT. Time Spent in Physical
 Activity and Sedentary Behaviors on the Working Day: The American Time Use Survey.
 Journal of Occupational and Environmental Medicine. 2011;53(12):1382.
 doi:10.1097/JOM.0b013e31823c1402
- Matthews CE, Berrigan D, Fischer B, et al. Use of previous-day recalls of physical
 activity and sedentary behavior in epidemiologic studies: results from four instruments. *BMC Public Health*. 2019;19(Suppl 2):478. doi:10.1186/s12889-019-6763-8
- Walmsley R, Chan S, Smith-Byrne K, et al. Reallocation of time between device measured movement behaviours and risk of incident cardiovascular disease. *Br J Sports Med.* Published online September 6, 2021. doi:10.1136/bjsports-2021-104050
- Suthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. *The Lancet Global Health*. 2018;6(10):e1077-e1086. doi:10.1016/S2214-109X(18)30357-7
- 385 9. Esliger DW, Tremblay MS. Physical activity and inactivity profiling: the next generation.
 386 *Can J Public Health*. 2007;98 Suppl 2:S195-207.
- 10. Dohrn IM, Kwak L, Oja P, Sjöström M, Hagströmer M. Replacing sedentary time with
 physical activity: a 15-year follow-up of mortality in a national cohort. *Clin Epidemiol*.
 2018;10:179-186. doi:10.2147/CLEP.S151613
- del Pozo Cruz B, Ahmadi MN, Lee IM, Stamatakis E. Prospective Associations of Daily
 Step Counts and Intensity With Cancer and Cardiovascular Disease Incidence and
 Mortality and All-Cause Mortality. *JAMA Intern Med.* 2022;182(11):1139-1148.
 doi:10.1001/jamainternmed.2022.4000
- Gilchrist SC, Howard VJ, Akinyemiju T, et al. Association of Sedentary Behavior With
 Cancer Mortality in Middle-aged and Older US Adults. *JAMA Oncology*. 2020;6(8):1210 1217. doi:10.1001/jamaoncol.2020.2045

13. Ensrud KE, Blackwell TL, Cauley JA, et al. Objective Measures of Activity Level and
 Mortality in Older Men. *Journal of the American Geriatrics Society*. 2014;62(11):2079 2087. doi:10.1111/jgs.13101

- 400 14. LaMonte MJ, Buchner DM, Rillamas-Sun E, et al. Accelerometer-Measured Physical
 401 Activity and Mortality in Women Aged 63 to 99. *Journal of the American Geriatrics*402 Society. 2018;66(5):886-894. doi:10.1111/jgs.15201
- 403 15. Guo W, Fensom GK, Reeves GK, Key TJ. Physical activity and breast cancer risk: results
 404 from the UK Biobank prospective cohort. *Br J Cancer*. 2020;122(5):726-732.
 405 doi:10.1038/s41416-019-0700-6
- 406 16. Hyde ET, LaCroix AZ, Evenson KR, et al. Accelerometer-measured physical activity and
 407 postmenopausal breast cancer incidence in the Women's Health Accelerometry
 408 Collaboration. *Cancer*. 2023;129(10):1579-1590. doi:10.1002/cncr.34699
- 409 17. Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure-Time Physical Activity
 410 With Risk of 26 Types of Cancer in 1.44 Million Adults. *JAMA Intern Med.*411 2016;176(6):816-825. doi:10.1001/jamainternmed.2016.1548
- 412 18. Bassett DR, Toth LP, LaMunion SR, Crouter SE. Step Counting: A Review of
 413 Measurement Considerations and Health-Related Applications. *Sports Med.*414 2017;47(7):1303-1315. doi:10.1007/s40279-016-0663-1
- 415 19. UK Biobank Limited. UK Biobank Enable your research. UK Biobank. Published June
 416 24, 2021. Accessed August 31, 2022. https://www.ukbiobank.ac.uk/enable-your-research
- Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for
 Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Medicine*. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 21. Doherty A, Jackson D, Hammerla N, et al. Large Scale Population Assessment of Physical
 Activity Using Wrist Worn Accelerometers: The UK Biobank Study. *PLOS ONE*.
 2017;12(2):e0169649. doi:10.1371/journal.pone.0169649
- 423 22. Small SR, Chan S, Walmsley R, et al. Development and Validation of a Machine Learning
 424 Wrist-worn Step Detection Algorithm with Deployment in the UK Biobank. Published
 425 online February 22, 2023:2023.02.20.23285750. doi:10.1101/2023.02.20.23285750
- 426 23. Saint-Maurice PF, Troiano RP, Bassett DR Jr, et al. Association of Daily Step Count and
 427 Step Intensity With Mortality Among US Adults. *JAMA*. 2020;323(12):1151-1160.
 428 doi:10.1001/jama.2020.1382
- 429 24. Conroy MC, Lacey B, Bešević J, et al. UK Biobank: a globally important resource for cancer research. *Br J Cancer*. 2023;128(4):519-527. doi:10.1038/s41416-022-02053-5
- 431 25. 2011 UK Townsend Deprivation Scores UK Data Service CKAN. Accessed June 28,
 432 2023. https://statistics.ukdataservice.ac.uk/dataset/2011-uk-townsend-deprivation-scores
- 433 26. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational
 434 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
 435 studies. *BMJ*. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD

| 436 437 438 | 27. | Cao Z, Xu C, Zhang P, Wang Y. Associations of sedentary time and physical activity with adverse health conditions: Outcome-wide analyses using isotemporal substitution model. <i>eClinicalMedicine</i> . 2022;48:101424. doi:10.1016/j.eclinm.2022.101424 |
|--------------------------|-----|---|
| 439 440 441 | 28. | Morris JS, Bradbury KE, Cross AJ, Gunter MJ, Murphy N. Physical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank. <i>Br J Cancer</i> . 2018;118(6):920-929. doi:10.1038/bjc.2017.496 |
| 442 443 444 | 29. | Friedenreich CM, Ryder-Burbidge C, McNeil J. Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. <i>Molecular Oncology</i> . 2021;15(3):790-800. doi:10.1002/1878-0261.12772 |
| 445 446 447 448 | 30. | Stamatakis E, Ahmadi MN, Friedenreich CM, et al. Vigorous Intermittent Lifestyle Physical Activity and Cancer Incidence Among Nonexercising Adults: The UK Biobank Accelerometry Study. <i>JAMA Oncology</i> . 2023;9(9):1255-1259. doi:10.1001/jamaoncol.2023.1830 |
| 449 450 | 31. | Morris JN, Hardman AE. Walking to Health. <i>Sports Med.</i> 1997;23(5):306-332. doi:10.2165/00007256-199723050-00004 |
| 451 452 453 | 32. | Ding D, Buskirk JV, Nguyen B, et al. Physical activity, diet quality and all-cause cardiovascular disease and cancer mortality: a prospective study of 346 627 UK Biobank participants. <i>Br J Sports Med.</i> 2022;56(20):1148-1156. doi:10.1136/bjsports-2021-105195 |
| 454 455 456 457 | 33. | Parada H, McDonald E, Bellettiere J, Evenson KR, LaMonte MJ, LaCroix AZ. Associations of accelerometer-measured physical activity and physical activity-related cancer incidence in older women: results from the WHI OPACH Study. <i>Br J Cancer</i> . 2020;122(9):1409-1416. doi:10.1038/s41416-020-0753-6 |
| 458 459 460 | 34. | Bassett DR, Troiano RP, Mcclain JJ, Wolff DL. Accelerometer-based Physical Activity: Total Volume per Day and Standardized Measures. <i>Medicine & Science in Sports & Exercise</i> . 2015;47(4):833-838. doi:10.1249/MSS.000000000000468 |
| 461 462 | 35. | UK Biobank Limited. UK Biobank Malignant Cancer Summary Report.; 2022. Accessed December 9, 2021. https://biobank.ndph.ox.ac.uk/~bbdatan/CancerSummaryReport.html |
| 463 464 465 | 36. | Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health- Related Characteristics of UK Biobank Participants With Those of the General Population. <i>Am J Epidemiol</i> . 2017;186(9):1026-1034. doi:10.1093/aje/kwx246 |
| 466 467 468 469 | 37. | Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. <i>BMJ</i> . 2020;368:m131. doi:10.1136/bmj.m131 |
| 470 | | |

471 **TABLES AND FIGURES**

- Table 1. Overall physical activity metrics by demographic characteristic in 86 556 UK Biobankparticipants.
- 474 Figure 1. Association of mean accelerometer-measured physical activity with risk of incident475 cancers in 86 556 UK Biobank participants.
- 476 Figure 2. Hazard ratios for balance between movement behaviours and incident physical-
- 477 activity-related cancer risk associated in 86 556 UK Biobank participants.
- 478 Figure 3. Dose-response associations between daily step count and physical-activity-related
- 479 cancer risk in 86 556 UK Biobank participants.
- 480 Table 2. Adjusted hazard ratios for peak 30-minute cadence and physical activity-related cancer
- 481 risk in 86 556 UK Biobank participants.

| Characteristic | | No. (%) | Overall acceleration (mg) | Daily step count Median (IQR) | Peak 30 min cadence (steps/min) Median (IQR) |
|---|------------------------------------|--------------|---------------------------------|----------------------------------|--|
| Overall | | 86 556 (100) | 27.3 (22.7-32.7) | 9 073 (6 834-11 686) | 91 (81-101) |
| Sex | Female | 48 478 (56) | 27.8 (23.2-33.1) | 9 004 (6 812-11 560) | 92 (82-102) |
| | Male | 38 078 (44) | 26.7 (22.0-32.3) | 9 152 (6 870-11 878) | 90 (81-100) |
| Age (years) | 40-49 | 7 693 (9) | 30.5 (25.6-36.7) | 9 393 (7 126-12 070) | 95 (85-105) |
| | 50-59 | 25 659 (30) | 29.1 (24.4-34.8) | 9 204 (6 996-11 913) | 93 (84-103) |
| | 60-69 | 38 214 (44) | 26.8 (22.3-31.9) | 9 166 (6 922-11 772) | 91 (81-100) |
| | 70-79 | 14 990 (17) | 24.3 (20.2-28.9) | 8 430 (6 255-10 868) | 87 (77-96) |
| Ethnicity | Non-white | 2 726 (3) | 28.5 (23.7-34.1) | 8 720 (6 508-11 376) | 91 (80-102) |
| | White | 83 830 (97) | 27.3 (22.6-32.7) | 9 084 (6 845-11 696) | 91 (81-101) |
| Quintiles of Townsend Deprivation Index | Least Deprived | 43 574 (50) | 27.4 (22.8-32.7) | 9 080 (6 922-11 633) | 90 (81-100) |
| | 2nd Quintile | 19 542 (23) | 27.3 (22.6-32.7) | 9 078 (6 817-11 656) | 91 (81-101) |
| | 3rd Quintile | 12 151 (14) | 27.4 (22.7-32.9) | 9 164 (6 816-11 862) | 93 (82-103) |
| | 4th Quintile | 8 381 (10) | 27.0 (22.1-32.7) | 8 970 (6 586-11 802) | 93 (82-103) |
| | Most Deprived | 2 908 (3) | 26.6 (21.6-32.4) | 8 812 (6 293-11 664) | 94 (81-104) |
| Education qualifications | School leaver | 19 817 (23) | 26.8 (22.0-32.2) | 8 621 (6 428-11 229) | 89 (79-99) |
| | Further education | 28 993 (33) | 27.3 (22.6-32.7) | 8 883 (6 644-11 543) | 90 (80-100) |
| | Higher education | 37 746 (44) | 27.6 (23.0-33.0) | 9 434 (7 208-12 009) | 93 (84-103) |
| Smoking status | Never | 49 736 (57) | 27.6 (23.0-33.1) | 9 183 (6 980-11 762) | 92 (82-102) |
| | Previous smoker | 30 805 (36) | 27.0 (22.4-32.4) | 8 984 (6 720-11 671) | 90 (80-100) |
| | Current, unknown cig/day | 2 351 (3) | 27.0 (22.3-32.2) | 9 037 (6 766-11 730) | 90 (80-100) |
| | Current, < 15 cig/day | 899 (1) | 25.6 (21.0-31.1) | 8 160 (5 989-10 690) | 86 (75-97) |
| | Current, $\geq 15 \text{ cig/day}$ | 2 765 (3) | 25.3 (20.5-30.8) | 8 108 (5 808-10 818) | 87 (75-96) |
| Alcohol consumption | Never | 4 859 (6) | 26.4 (21.5-32.1) | 8 530 (6 120-11 313) | 89 (78-100) |
| | < 3 times/week | 39 335 (45) | 27.1 (22.4-32.5) | 8 762 (6 554-11 379) | 90 (80-100) |
| | 3+ times/week | 42 362 (49) | 27.6 (23.0-33.0) | 9 411 (7 186-12 000) | 92 (83-102) |
| Body mass index, kg/m ² | \leq 24.9 kg/m ² | 33 234 (38) | 29.4 (24.6-35.2) | 9 754 (7 548-12 401) | 95 (85-105) |
| | 25-29.9 kg/m ² | 36 206 (42) | 26.9 (22.5-32.1) | 9 094 (6 916-11 653) | 91 (81-100) |
| | $30 + kg/m^2$ | 17 116 (20) | 24.2 (20.0-29.1) | 7 610 (5 564-10 060) | 85 (74-95) |
| Fruit and vegetable consumption | < 3 servings/day | 3 683 (4) | 25.6 (20.7-30.8) | 8 187 (5 930-10 973) | 88 (78-99) |
| | 3-4.9 servings/day | 14 167 (16) | 26.7 (22.0-32.0) | 8 781 (6 580-11 342) | 90 (80-100) |

Table 1. Overall physical activity metrics by demographic characteristic in 86 556 UK Biobank participants.

| Characteristic | | No. (%) | Overall acceleration (mg) | Daily step count Median (IQR) | Peak 30 min cadence (steps/min) Median (IQR) |
|--------------------------------------|-----------------------|--------------|---------------------------------|----------------------------------|--|
| | 5-7.9 servings/day | 36 127 (42) | 27.3 (22.7-32.7) | 9 117 (6 918-11 682) | 91 (82-101) |
| | 8+ servings/day | 31 857 (37) | 27.9 (23.2-33.3) | 9 232 (6 981-11 922) | 92 (82-101) |
| | Missing | 722 (1) | 26.4 (21.2-32.6) | 8 914 (6 127-11 825) | 90 (79-100) |
| Red and processed meat consumption | Less than 1 time/week | 6 802 (8) | 29.3 (24.3-35.1) | 9 674 (7 256-12 397) | 96 (85-106) |
| | 1-2.9 times/week | 33 047 (38) | 27.5 (22.9-32.9) | 9 091 (6 906-11 682) | 92 (82-102) |
| | 3-4.9 times/week | 25 399 (29) | 27.1 (22.5-32.5) | 8 992 (6 768-11 582) | 91 (81-100) |
| | 5+ times/week | 20 927 (24) | 26.6 (21.9-32.0) | 8 964 (6 676-11 567) | 90 (80-99) |
| | Missing | 381 (0) | 28.2 (21.5-34.1) | 9 158 (6 190-12 077) | 91 (79-101) |
| Self-reported usual walking pace | Brisk pace | 41 087 (47) | 29.0 (24.3-34.6) | 9 630 (7 422-12 250) | 94 (85-104) |
| | Steady average pace | 41 381 (48) | 26.2 (21.8-31.2) | 8 737 (6 575-11 294) | 89 (80-99) |
| | Slow pace | 3 907 (5) | 21.9 (17.6-26.8) | 6 352 (4 150-8 870) | 77 (64-89) |
| | None of the above | 76 (0) | 23.5 (18.5-29.3) | 5 527 (2 945-9 778) | 78 (54-87) |
| | Missing | 105 (0) | 18.9 (13.9-23.5) | 3 397 (1 102-5 684) | 56 (26-72) |
| Self-rated overall health | Excellent | 19 332 (22) | 29.2 (24.5-35.0) | 9 765 (7 566-12 386) | 95 (85-104) |
| | Good | 51 914 (60) | 27.4 (22.8-32.6) | 9 140 (6 946-11 727) | 91 (82-101) |
| | Fair | 13 079 (15) | 25.0 (20.6-30.2) | 8 100 (5 885-10 650) | 87 (76-97) |
| | Poor | 2 089 (2) | 22.1 (17.6-27.2) | 6 378 (4 064-8 983) | 78 (64-90) |
| | Missing | 142 (0) | 23.3 (19.6-28.4) | 7 928 (5 528-10 270) | 85 (75-95) |
| Wear season | Spring | 19 875 (23) | 27.7 (23.0-33.2) | 9 207 (6 946-11 880) | 92 (82-102) |
| | Summer | 22 946 (27) | 27.9 (23.1-33.4) | 9 514 (7 208-12 186) | 91 (82-101) |
| | Autumn | 25 518 (29) | 27.2 (22.7-32.6) | 8 966 (6 794-11 522) | 91 (81-101) |
| | Winter | 18 217 (21) | 26.3 (21.9-31.5) | 8 518 (6 398-11 058) | 90 (80-101) |
| Females ^a | | 48 478 (100) | 27.8 (23.2-33.1) | 9 004 (6 812-11 560) | 92 (82-102) |
| Number of live births | 0 | 10 373 (21) | 27.9 (23.3-33.4) | 9 060 (6 792-11 700) | 94 (83-105) |
| | 1-2 | 27 689 (57) | 27.8 (23.3-33.1) | 8 964 (6 796-11 490) | 92 (82-101) |
| | 3+ | 10 403 (21) | 27.7 (23.1-32.9) | 9 080 (6 863-11 606) | 91 (81-101) |
| | Missing | 13 (0) | 29.6 (27.4-35.4) | 9 048 (8 602-12 202) | 91 (87-101) |
| Had menopause | No | 13 166 (27) | 30.0 (25.2-35.6) | 9 304 (7 094-11 913) | 95 (85-105) |
| | Yes | 28 028 (58) | 27.1 (22.7-32.1) | 9 022 (6 838-11 550) | 91 (81-101) |
| | Missing/Not sure | 7 284 (15) | 26.8 (22.3-31.9) | 8 406 (6 290-10 923) | 89 (79-100) |
| Hormone-replacement therapy ever use | No | 31 109 (64) | 28.5 (24.0-34.0) | 9 215 (7 016-11 805) | 94 (83-103) |
| | Yes | 17 283 (36) | 26.4 (22.1-31.3) | 8 612 (6 473-11 102) | 89 (79-99) |

| Characteristic | | No. (%) | Overall acceleration (mg) | Daily step count Median (IQR) | Peak 30 min cadence (steps/min) Median (IQR) |
|----------------------------------|---------|-------------|---------------------------------|----------------------------------|--|
| | Missing | 86 (0) | 26.2 (21.6-32.1) | 7 854 (6 521-10 788) | 87 (79-100) |
| Oral contraceptive pill ever use | No | 7 027 (14) | 26.9 (22.4-32.3) | 8 816 (6 685-11 295) | 91 (80-101) |
| | Yes | 41 381 (85) | 27.9 (23.4-33.2) | 9 037 (6 835-11 591) | 92 (82-102) |
| | Missing | 70 (0) | 29.2 (23.8-33.0) | 8 848 (6 806-11 994) | 90 (83-104) |

Activity metrics reported as median (interquartile range (IQR)). TDI = Townsend Deprivation Index, mg = milligravity, min=minute, cig = cigarettes, kg/m² = kilograms/meters². ^aAmong female participants, N=48 478.

Figure 1. Association of mean accelerometer-measured physical activity with risk of incident cancers in 86 556 UK Biobank participants.



The standard deviation (SD) of total physical activity (PA) was 8.3 milligravity unit in the main analytical sample. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards regression model. Cases are incident cancers. PA-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used age as the underlying time variable and were adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. For breast cancer and endometrial cancer, models were adjusted for use of oral contraception, use of hormone replacement therapy, menopausal status, and parity. Participants were limited to males for prostate cancer (N=38 078), females for breast cancer (N=48 478), and females without a history of hysterectomy for endometrial cancer (N=41 010).

Figure 2. Hazard ratios for balance between movement behaviours and incident physical-activity-related cancer risk associated in 86 556 UK Biobank participants.



Hazard ratios are relative to the mean behaviour composition (8.1 hours/day sleep, 10.5 hours/day sedentary behaviour (SB), 4.9 hours/day light intensity physical activity behaviours (LIPA), 0.46 hours/day (27.4 minutes/day) moderate-vigorous intensity physical activity behaviours (MVPA)). Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used attained age as the underlying time variable and were adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Models are based on 2 669 events in 86 556 participants. hr = hour.



Figure 3. Dose-response associations between daily step count and physical-activity-related cancer risk in 86 556 UK Biobank participants.

Estimated hazard ratios and 95% confidence intervals were computed using a Cox proportional hazards regression model with restricted cubic spline functions. Observations were trimmed at the 1% and 99% of the distribution and 3 knots were placed at the 5th, 50th, and 95th percentile for the exposures. The ~10th percentile was set as the referent group (5 000 steps). Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). The male model was limited to 38 078 participants and the female model was limited to 48 478 participants. Models used attained age as the underlying time variable and were adjusted for ethnicity, smoking status, alcohol consumption, deprivation, and education. The overall model (A) was further adjusted for sex and the female model (C) was further adjusted for use of oral contraception, use of hormone replacement therapy, menopausal status, and parity. The shading on the lower axis represents sample clustering of daily step counts.

Table 2. Adjusted hazard ratios for peak 30-minute cadence and physical activity-related cancer risk in 86 556 UK Biobank participants.

| | Model 1 | Model 2 |
|--|--------------------|--------------------|
| Peak 30-minute cadence (steps/minute) | HR (95% CI) | HR (95% CI) |
| 60 | 1.14 (1.02 - 1.27) | 1.10 (0.98 - 1.23) |
| 70 (REF, $\sim 10^{\text{th}}$ percentile) | 1.00 (1.00 - 1.00) | 1.00 (1.00 - 1.00) |
| 80 | 0.88 (0.80 - 0.96) | 0.91 (0.83 - 1.00) |
| 90 | 0.82 (0.73 - 0.92) | 0.89 (0.78 - 1.01) |
| 100 | 0.77 (0.69 - 0.87) | 0.88 (0.76 - 1.02) |
| 110 | 0.74 (0.65 - 0.84) | 0.87 (0.73 - 1.04) |
| 120 (~95 th percentile) | 0.72 (0.59 - 0.89) | 0.88 (0.69 - 1.14) |
| <i>P</i> value for linear trend | < 0.001 | 0.05 |

Estimated hazard ratios (HRs) and 95% confidence intervals (CIs) were computed using a Cox proportional hazards regression model with restricted cubic spline functions. Observations were trimmed at the 1% and 99% of the distribution and 3 knots were placed at the 5th, 50th, and 95th percentile for the exposures. The ~10th percentile was set as the referent (REF) group (70 steps per minute). Models used age as the underlying time variable and were adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Model 2: Model 1 + median daily step count. Physical activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast).

<u>eTABLES</u>

eTable 1: Definition of variables from the UK Biobank data.

eTable 2. Coding and number of site-specific cancer incident cases in UK Biobank participants.

eTable 3. Tabulation of number of incident primary events per cancer site in 86 556 UK Biobank participants.

eTable 4. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.

eTable 5. Sequential model adjustments for total physical activity (milligravity units) and risk of incident cancer in 86 556 UK Biobank participants.

eTable 6. Sequential model adjustments for quintile of total physical activity (milligravity units), quintile of median daily step count, and risk of incident physical activity-related cancer in 86 556 UK Biobank participants.

eTable 7. Changes in behaviour time and physical-activity-related cancer risk in 86 556 UK Biobank participants.

eTable 8. Sequential model adjustments for median daily step count and physical-activity-related cancer risk in 86 556 UK Biobank participants.

eTable 9. Sequential model adjustments for total physical activity (milligravity units) and risk of incident cancer in the UK Biobank among 38 078 male UK Biobank participants.

eTable 10. Sequential model adjustments for total physical activity (milligravity units) and risk of incident cancer in the UK Biobank among 48 478 female UK Biobank participants.

eTable 11. Sex-specific adjusted hazard ratios for median daily step count and physical-activity-related cancer risk in 38 078 male UK Biobank participants and 48 478 female UK Biobank participants.

eTable 12. Models for quintile of total physical activity (milligravity units), quintile of median daily step count, and risk of incident physical-activity-related cancer in UK Biobank participants who were never smokers (N=49 736).

eTable 13. Models for quintile of total physical activity (milligravity units), quintile of median daily step count, and risk of incident physical-activity-related cancer in 86 556 UK Biobank participants before and after removing the first two years of follow-up (N=83 435).

eFIGURES

eFigure 1. Participant flow diagram for the analysis of daily physical activity and step count measured by accelerometers in UK Biobank participants.

eFigure 2. Hazard Ratios reallocating time to a given movement behaviour from all other behaviours proportionally and incident physical-activity-related cancer in 86 556 UK Biobank participants.

eFigure 3. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after adjusting for body mass index as a sensitivity analysis.

eFigure 4. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after adjusting for dietary factors as a sensitivity analysis.

eFigure 5. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model among 48 478 female participants (blue) and 38 078 male participants (red).

eFigure 6. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after restricting to never smokers (red, N=49 736).

eFigure 7. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after removing the first two years of follow-up (red, N=83 435).

| Characteristic | Source | Notes | UK Biobank field | Coding Notes |
|---|---------------------------------------|--|------------------------|--------------|
| OUTCOME | | | | |
| Age at first cancer event | Cancer Registry, Death Registry | First ICD-10 code in cancer registry or death registry data. Full list of ICD-10 and ICD-O-3 codes are described in detail in eTable 1. | Derived from 100092 | |
| Age at loss-to-follow up | Death Registry | | Derived from 100093 | |
| EXPOSURE | • | | | • |
| Total physical activity | Accelerometry | Derived using the Biobank Accelerometer Analysis Tool, "accelerometer", version 7.1.0. Details: https://github.com/OxWearables/biobankA ccelerometerAnalysis | | |
| Step count | Accelerometry | Derived using the "stepcount" tool, version 3.1.1. Details can be found at: https://github.com/OxWearables/stepcount | | |
| Peak 30 second cadence | Accelerometry | Derived using the "stepcount" tool, version 3.1.1. Details can be found at: https://github.com/OxWearables/stepcount | | |
| Sleep | Accelerometry | Derived using the Biobank Accelerometer Analysis Tool, "accelerometer", version 7.1.0. Details: https://github.com/OxWearables/biobankA ccelerometerAnalysis | | |
| Sedentary behaviour | Accelerometry | Derived using the Biobank Accelerometer Analysis Tool, "accelerometer", version 7.1.0. Details: https://github.com/OxWearables/biobankA ccelerometerAnalysis | | |
| Light intensity physical activity behaviour | Accelerometry | Derived using the Biobank Accelerometer Analysis Tool, "accelerometer", version 7.1.0. Details: https://github.com/OxWearables/biobankA ccelerometerAnalysis | | |

eTable 1. Definition of variables from the UK Biobank data.

| Characteristic | Source | Notes | UK Biobank field | Coding Notes |
|--|-----------------|--|-------------------------------|--|
| Moderate-vigorous intensity physical activity behaviours | Accelerometry | Derived using the Biobank Accelerometer Analysis Tool, "accelerometer", version 7.1.0. Details: https://github.com/OxWearables/biobankA ccelerometerAnalysis | | |
| EXCLUSION VARIABLES - | MAIN ANALYSIS | · · · | | • |
| Prior incident cancer | Cancer Registry | Cancer-related ICD-10 codes in cancer registry data prior to accelerometry wear date. | Derived from 100092 | |
| ADJUSTMENT VARIABLES | - MAIN ANALYSIS | | | |
| Age | Baseline | Attained age was the underlying timescale in survival analyses; participants entered the study at the end of accelerometer wear. | Derived from 90011, 34, 52 | |
| Sex | Baseline | | 31 | Male, Female |
| Ethnicity | Baseline | | Derived from 21000 | White, non-White |
| Smoking status | Baseline | | Derived from 20116, 3456 | Never, previous, current unknown cigarettes/day, current < 15 cigarettes per day, or current ≥ 15 cigarettes per day |
| Alcohol consumption | Baseline | | Derived from 1558 | Never, <3 times per week, or ≥ 3 times per week |
| Education | Baseline | | Derived from 6138 | School leaver, Further education (education beyond O-Levels/CSEs, excluding college/ university degree) and Higher education (college/university degree) |
| Townsend Deprivation Index | Baseline | Townsend Deprivation Index of address at time of UKB baseline assessment. | Derived from 189 | Divided by quintile of the UK population based on the 2011 UK census ^a |
| Parity | Baseline | Among females only | Derived from 2734 | 0, 1-2, 3+, Missing |
| Use of hormone replacement therapy | Baseline | Among females only | Derived from 2814 | No, Yes, Missing |

| Characteristic | Source | Notes | UK Biobank field | Coding Notes |
|---|------------------|--------------------|---|--|
| Use of oral contraceptives pill | Baseline | Among females only | Derived from 2784 | No, Yes, Missing |
| Menopausal status | Baseline | Among females only | Derived from 2724 | No, Yes, Not sure or Missing |
| ADJUSTMENT VARIABLES | – SENSITIVITY AN | IALYSIS | | |
| Body mass index | Baseline | | Derived from 21001 | For descriptive analyses: Underweight/Normal weight (≤24.9 kilograms/meters ²), Overweight (25- 29.9 kilograms/meters ²), Obese (30+ kilograms/meters ²) |
| Frequency of red and processed meat consumption | Baseline | | Derived from 1369, 1379, 1389, 1349 | <1, 1–2.9, 3–4.9, 5+ times/week, Missing |
| Frequency of fresh fruit and vegetable consumption | Baseline | | Derived from 1289, 1299, 1309 | <3, 3–4.9, 5–7.9, 8+ servings/day, Missing |
| DESCRIPTIVE VARIABLES | – DESCRIPTIVE T | ABLES | | |
| Self-reported usual Walking pace | | | 924 | Slow pace, Steady average pace, Brisk pace, None of the above |
| Self-rated overall health | | | 2178 | Excellent, Good, Fair, Poor |
| Wear season | | | Derived from 90001 | Winter, Spring, Summer, Autumn |

^a Deprivation based on the 2011 UK census (2011 UK Townsend Deprivation Scores - UK Data Service CKAN. Accessed June 28, 2023. https://statistics.ukdataservice.ac.uk/dataset/2011-uk-townsend-deprivation-scores)

| Cancer site | Cancer registry ICD-10 (if applicable, ICD-O-3) ^e | Death registry ICD-10 codes |
|-----------------------------------|--|---|
| Physical-activity-related cancers | | |
| Bladder | C670-679 | C670-679 |
| Breast ^a | C500-509 | C500-509 |
| Colon | C180-189 | C180-189 |
| Endometrial ^b | C540-549 and C559 | C540-549 and C559 |
| Gastric cardia | C160 | C160 |
| Head and neck | C000-009 C019-029, C079-C089, C040-049, C030-039, C050-059, C060-069, C110-119 C090-099, C100-109, C129, C130-139, C140, C142, C148, C320-329 | C000-009 C019-029, C079-C089, C040- 049, C030-039, C050-059, C060-069, C110-119 C090-099, C100-109, C129, C130-139, C140, C142, C148, C320-329 |
| Kidney | C640-659 | C640-659 |
| Liver | C220-229 | C220-229 |
| Lung | C340-349 | C340-349 |
| Myeloid leukaemia | Any histology of 9840, 9861, 9865-9867, 9869, 9871-9874, 9895-9897, 9898, 9910-9911,9920, 9891, 9863, 9875-9876, 9945-9946, 9860, 9930 | Histology based |
| Myeloma | C880-889, C900-909 ^f | C880-889, C900-909 |
| Oesophageal adenocarcinoma | C150-159 & histologies: 8140, 8142, 8144, 8261, 8310, 8480, 8481, 8570 | Histology based |
| Rectal | C190-209 | C190-209 |
| Other site-specific cancers | | |
| Anal | C210-219 | C210-219 |
| Brain | C710-719 | C710-719 |
| Cervix ^a | C530-539 | C530-539 |
| Gallbladder | C230-239 | C230-239 |
| Gastric non-cardia | C161-169 | C161-169 |
| Hodgkin lymphoma | C810-819 ^f | C810-819 |
| Melanoma skin | C430-439, only histologies: 8720-8790 | C430-439 |

eTable 2. Coding and number of site-specific cancer incident cases in UK Biobank participants.

| Cancer site | Cancer registry ICD-10 (if applicable, ICD-O-3) ^e | Death registry ICD-10 codes |
|-------------------------------------|---|---|
| Non-Hodgkin lymphoma | C820-869, C911, or any histologies of 9823, 9670 | C820-869, C911 |
| Chronic lymphocytic leukaemia | C911 | C911 |
| Other leukaemia | C910-959, excluding cases classified as Myeloid leukaemia and non-Hodgkin lymphoma ^f | C910-959, excluding cases classified as Myeloid leukaemia and non-Hodgkin lymphoma ^f |
| Oesophageal squamous cell carcinoma | C150-159, only histologies: 8041,8070,8071,8072,8074 | Histology based |
| Ovary⁰ | C560-569 | C560-569 |
| Pancreas | C250-259 | C250-259 |
| Prostate ^d | C610-619 | C610-619 |
| Small intestine | C170-179 | C170-179 |
| Thyroid | C730-739 | C730-739 |

^aAmong females, ^bAmong females with no history of hysterectomy, ^cAmong females with no history of bilateral oophorectomy, ^dAmong males.

^eUnless stated, definitions exclude ICD-O-3 histology codes 9050-9055, 9140, 9590-9992 cell types, which includes Kaposi sarcoma (9140), mesothelioma (9050–9055), lymphomas, leukaemias, myelomas, lymphoreticular, and immunoproliferative diseases (9050-9055, 9140, 9590-9992). ^fUnless stated, definitions exclude ICD-O-3 histology codes 9050-9055 and 9140, which includes Kaposi sarcoma (9140) and mesothelioma (9050–9055).

| | Overall | Male | Female |
|-------------------------------------|----------|----------|-----------------|
| Cancer type | N=86 556 | N=38 078 | N=48 478 |
| Physical-activity-related cancers | 2 669 | 898 | 1 771 |
| Bladder | 109 | 86 | 23 |
| Breast ^a | 995 | NA | 995 |
| Colon | 381 | 207 | 174 |
| Endometrial ^b | 153 | NA | 153 |
| Gastric cardia | 22 | 18 | <5 ^a |
| Head and neck | 88 | 68 | 20 |
| Kidney | 141 | 83 | 58 |
| Liver | 60 | 34 | 26 |
| Lung | 295 | 148 | 147 |
| Myeloid leukaemia | 43 | 18 | 25 |
| Myeloma | 107 | 61 | 46 |
| Oesophageal adenocarcinoma | 68 | 56 | 12 |
| Rectal | 209 | 121 | 88 |
| Other site-specific cancers | | | |
| Anal | 26 | 6 | 20 |
| Brain | 79 | 42 | 37 |
| Cervix ^a | 12 | NA | 12 |
| Gallbladder | 10 | 6 | <5 ^a |
| Gastric non-cardia | 40 | 25 | 15 |
| Hodgkin lymphoma | 12 | 7 | 5 |
| Melanoma skin | 328 | 181 | 147 |
| Non-Hodgkin lymphoma | 316 | 176 | 140 |
| Chronic lymphocytic leukaemia | 76 | 49 | 27 |
| Oesophageal squamous cell carcinoma | 29 | 12 | 17 |
| Other leukaemia | 27 | 18 | 9 |
| Ovary ^c | 66 | NA | 66 |
| Pancreas | 145 | 80 | 65 |
| Prostate ^d | 1380 | 1380 | NA |
| Small intestine | 30 | 14 | 16 |
| Thyroid | 43 | 15 | 28 |

eTable 3. Tabulation of number of incident primary events per cancer site in 86 556 UK Biobank participants.

Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). ^aAmong females, ^bAmong females with no history of hysterectomy, ^cAmong males, ^dAmong females with no history of bilateral oophorectomy. ^eUK Biobank policy states that tables should have a minimum number of 5 reported participants within a cell.

| | ltem No. | Recommendation | Page No. |
|------------------------------|-------------|--|----------------------------|
| | | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1, 3 |
| Title and abstract | 1 | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 3 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 5-6 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5-6 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5-9 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 6-7 |
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study—For matched studies, give matching criteria and number of exposed and | 6-8 |
| | | <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case | NA |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 6-9, eTable 1, eTable 2 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 6-9, eTable 1 |

eTable 4. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.

| | ltem No. | Recommendation | Page No. |
|------------------------|-------------|--|----------------------------|
| Bias | 9 | Describe any efforts to address potential sources of bias | 9 |
| Study size | 10 | Explain how the study size was arrived at | 6-8, eFigure 1 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 6-9, eTable 1 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | 8-10 |
| | | (b) Describe any methods used to examine subgroups and interactions | 9 |
| | | (c) Explain how missing data were addressed | 6-9, eTable1, eFigure 1 |
| | | (d) Cohort study—If applicable, explain how loss to follow-up was addressed | |
| | | Case-control study—If applicable, explain how matching of cases and controls was | |
| | | addressed | 8, eFigure 1 |
| | | Cross-sectional study—If applicable, describe analytical methods taking account of sampling | |
| | | strategy | |
| | | (<u>e</u>) Describe any sensitivity analyses | 9 |
| | | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, | |
| Participants | 13* | examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | eFigure 1 |
| | | (b) Give reasons for non-participation at each stage | eFigure 1 |
| | | (c) Consider use of a flow diagram | eFigure 1 |
| Descriptivo data | 1.1* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information | Table 1 |
| | 14 | on exposures and potential confounders | |
| | | (b) Indicate number of participants with missing data for each variable of interest | Table 1 |
| | | (c) Cohort study—Summarise follow-up time (eg, average and total amount) | 10 |
| Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time | 10, eTable 3 |
| | | Case-control study—Report numbers in each exposure category, or summary measures of exposure | NA |
| | | Cross-sectional study—Report numbers of outcome events or summary measures | NA |

| | ltem No. | Recommendation | Page No. |
|-------------------|-------------|---|-----------------------------------|
| Main results | 16 | (<i>a</i>) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Table 2, eTables 5-13. |
| | | (b) Report category boundaries when continuous variables were categorized | eTable 6, eTable 12, eTable 13 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 12-13 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10-12 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 15-16 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 16 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 15-16 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 19-20 |

eTable 5. Sequential model adjustments for total physical activity (milligravity units) and risk of incident cancer in 86 556 UK Biobank participants.

| | | Model 1 | Model 2 | Model 3 |
|----------------------------------|------------|----------------------|----------------------|----------------------|
| Cancer type | Case count | HR per 1 SD (95% CI) | HR per 1 SD (95% CI) | HR per 1 SD (95% CI) |
| Physical-activity-related cancer | 2 669 | 0.85 (0.81-0.88) | 0.85 (0.81-0.89) | 0.88 (0.84-0.92) |
| Bladder | 109 | 0.63 (0.50-0.80) | 0.69 (0.55-0.87) | 0.71 (0.56-0.90) |
| Breast | 995 | 0.90 (0.85-0.97) | 0.91 (0.85-0.97) | 0.91 (0.85-0.98) |
| Colon | 381 | 0.84 (0.75-0.94) | 0.84 (0.75-0.95) | 0.88 (0.78-0.99) |
| Endometrial | 153 | 0.76 (0.63-0.91) | 0.78 (0.65-0.93) | 0.89 (0.74-1.07) |
| Gastric cardia | 22 | 0.31 (0.17-0.56) | 0.39 (0.22-0.70) | 0.47 (0.25-0.85) |
| Head and neck | 88 | 0.75 (0.59-0.97) | 0.84 (0.66-1.07) | 0.82 (0.64-1.04) |
| Kidney | 141 | 0.80 (0.66-0.98) | 0.86 (0.71-1.04) | 0.89 (0.73-1.08) |
| Liver | 60 | 0.62 (0.45-0.86) | 0.65 (0.47-0.90) | 0.72 (0.52-1.00) |
| Lung | 295 | 0.64 (0.55-0.74) | 0.75 (0.65-0.86) | 0.77 (0.66-0.89) |
| Myeloid Leukaemia | 43 | 0.95 (0.68-1.33) | 0.97 (0.78-1.19) | 1.00 (0.81-1.24) |
| Myeloma | 107 | 0.94 (0.76-1.16) | 0.97 (0.70-1.36) | 1.03 (0.74-1.45) |
| Oesophageal adenocarcinoma | 68 | 0.78 (0.59-1.04) | 0.89 (0.68-1.16) | 1.01 (0.77-1.33) |
| Rectal | 209 | 0.96 (0.83-1.12) | 0.99 (0.85-1.14) | 1.00 (0.86-1.16) |
| Melanoma skin | 328 | 0.90 (0.79-1.01) | 0.89 (0.79-1.01) | 0.90 (0.80-1.03) |
| Non-Hodgkin lymphoma | 316 | 0.85 (0.75-0.96) | 0.85 (0.75-0.97) | 0.87 (0.76-0.99) |
| Pancreas | 145 | 0.84 (0.69-1.01) | 0.86 (0.71-1.04) | 0.90 (0.74-1.09) |
| Prostate | 1 380 | 1.05 (0.99-1.11) | 1.04 (0.98-1.10) | 1.03 (0.97-1.10) |

The standard deviation (SD) of physical activity was 8.3 milligravity unit in the main analytical sample. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. Models used age as the underlying time variable. Model 1: Unadjusted. Model 2: adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Model 3: Model 2 + adjusted for body mass index. For breast cancer and endometrial cancer, Model 2 and Model 3 were adjusted for ever use of oral contraception, ever use of hormone replacement therapy, menopausal status, and parity. Participants were limited to males for prostate cancer (N=38 078), females for breast cancer (N=48 478), and females without a history of hysterectomy for endometrial cancer (N=41 010).

eTable 6. Sequential model adjustments for quintile of total physical activity (milligravity units), quintile of median daily step count, and risk of incident physical-activity-related cancer in 86 556 UK Biobank participants.

| | | | Model 1 | Model 2 | Model 3 | Model 4 |
|---|--------|------------|------------------|------------------|------------------|------------------|
| Quintile of total daily physical activity | Total | Case count | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Q1: <21.6 | 17 311 | 718 | REF | REF | REF | REF |
| Q2: 21.6-25.4 | 17 311 | 569 | 0.84 (0.75-0.93) | 0.84 (0.75-0.93) | 0.86 (0.77-0.96) | 0.84 (0.75-0.94) |
| Q3: 25.5-29.1 | 17 311 | 522 | 0.80 (0.71-0.89) | 0.79 (0.71-0.89) | 0.83 (0.74-0.93) | 0.80 (0.71-0.90) |
| Q4: 29.2-34.2 | 17 311 | 460 | 0.74 (0.65-0.83) | 0.74 (0.65-0.83) | 0.78 (0.69-0.88) | 0.75 (0.66-0.84) |
| Q5: 34.3+ | 17 312 | 400 | 0.69 (0.61-0.78) | 0.70 (0.61-0.79) | 0.76 (0.66-0.86) | 0.71 (0.62-0.80) |
| P value for linear trend | | | <0.001 | <0.001 | <0.001 | <0.001 |
| Quintile of daily step count | Total | Case count | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| Q1: < 6 319 | 17 308 | 687 | REF | REF | REF | REF |
| Q2: 6 319-8 187 | 17 302 | 542 | 0.80 (0.71-0.90) | 0.82 (0.74-0.92) | 0.85 (0.76-0.95) | 0.85 (0.74-0.98) |
| Q3: 8 188-10 009 | 17 315 | 513 | 0.76 (0.68-0.85) | 0.79 (0.71-0.89) | 0.83 (0.74-0.93) | 0.83 (0.72-0.95) |
| Q4: 10 010-12 415 | 17 318 | 494 | 0.74 (0.66-0.83) | 0.78 (0.69-0.88) | 0.83 (0.73-0.93) | 0.79 (0.69-0.91) |
| Q5: 12 416+ | 17 313 | 433 | 0.66 (0.59-0.75) | 0.71 (0.63-0.80) | 0.76 (0.67-0.86) | 0.76 (0.66-0.88) |
| P value for linear trend | | | <0.001 | <0.001 | <0.001 | <0.001 |

Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used age as the underlying time variable. Model 1: Unadjusted. Model 2: adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Model 3: Model 2 + adjusted for body mass index. Model 4: Model 2 + adjusted for fruit and vegetable intake, and red and processed meat intake. REF = reference.

eTable 7. Changes in behaviour time and physical-activity-related cancer risk in 86 556 UK Biobank participants.

| | Model 1 | Model 2 | Model 3 | Model 4 |
|----------------------------|------------------|------------------|------------------|------------------|
| Change in behaviour time | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) |
| 1 hour/day to LIPA from SB | 0.97 (0.95-1.00) | 0.94 (0.92-0.96) | 0.95 (0.93-0.97) | 0.94 (0.92-0.96) |
| 1 hour/day to MVPA from SB | 0.87 (0.84-0.90) | 0.92 (0.89-0.95) | 0.94 (0.91-0.98) | 0.92 (0.89-0.95) |
| 1 hr/day to Any PA from SB | 0.94 (0.93-0.96) | 0.93 (0.91-0.95) | 0.94 (0.92-0.96) | 0.93 (0.91-0.95) |
| 1 hr/day to MVPA from LIPA | 0.90 (0.86-0.93) | 0.99 (0.94-1.03) | 1.00 (0.96-1.05) | 0.99 (0.94-1.03) |

Hazard ratios (HR) and 95% confidence intervals (CI for incident physical-activity-related cancer associated with reallocating time to from one behaviour to another behaviour. Models are based on 2 669 events in 86 556 participants. HRs are relative to the mean behaviour composition (8.1 hours/day sleep, 10.5 hours/day sedentary behaviour (SB), 4.9 hours/day light intensity physical activity behaviours (LIPA), 0.46 hours/day (27.4 minutes/day) moderate-vigorous intensity physical (MVPA) activity behaviours). The "Any PA" category represents time in either LIPA or MVPA and was generated using a combined category for LIPA and MVPA activity time. Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used age as the underlying time variable. Model 1: Unadjusted. Model 2: adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Model 3: Model 2 + adjusted for body mass index. Model 4: Model 2 + adjusted for fruit and vegetable intake, and red and processed meat intake. Models are based on 2 669 events in 86 556 participants.

| | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|--------------------|--------------------|--------------------|--------------------|--------------------|
| Median daily steps | HR (95% CI) |
| 3 000 | 1.27 (1.11 - 1.45) | 1.22 (1.07 - 1.40) | 1.19 (1.04 - 1.36) | 1.22 (1.07 - 1.39) | 1.22 (1.04 - 1.44) |
| 5 000 (REF, ~10 th percentile) | 1.00 (1.00 - 1.00) | 1.00 (1.00 - 1.00) | 1.00 (1.00 - 1.00) | 1.00 (1.00 - 1.00) | 1.00 (1.00 - 1.00) |
| 7 000 | 0.86 (0.80 - 0.92) | 0.88 (0.82 - 0.94) | 0.90 (0.83 - 0.96) | 0.88 (0.82 - 0.94) | 0.88 (0.80 - 0.96) |
| 9 000 | 0.79 (0.71 - 0.87) | 0.82 (0.74 - 0.90) | 0.85 (0.77 - 0.94) | 0.82 (0.74 - 0.91) | 0.82 (0.73 - 0.93) |
| 11 000 | 0.76 (0.68 - 0.84) | 0.79 (0.71 - 0.88) | 0.84 (0.75 - 0.93) | 0.80 (0.72 - 0.89) | 0.79 (0.70 - 0.90) |
| 13 000 | 0.73 (0.65 - 0.82) | 0.77 (0.69 - 0.86) | 0.82 (0.73 - 0.92) | 0.78 (0.69 - 0.87) | 0.78 (0.67 - 0.89) |
| 16 000 (~95 th percentile) | 0.66 (0.57 - 0.77) | 0.71 (0.61 - 0.82) | 0.76 (0.65 - 0.88) | 0.72 (0.61 - 0.83) | 0.75 (0.62 - 0.90) |
| P value for linear trend | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |

eTable 8. Sequential model adjustments for median daily step count and physical-activity-related cancer risk in 86 556 UK Biobank participants.

Estimated hazard ratios (HR) and 95% confidence intervals (CI) were computed using a Cox proportional hazards model with restricted cubic spline functions. Observations were trimmed at the 1% and 99% of the distribution and 3 knots were placed at the 5th, 50th, and 95th percentile for the exposures in the main sample. The ~10th percentile was set as the referent group (5 000 steps). Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used age as the underlying time variable. Model 1: Unadjusted. Model 2: adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Model 3: Model 2 + adjusted for body mass index. Model 4 + adjusted for fruit and vegetable intake, and red and processed meat intake. Model 5: Model 2 with 2-year exclusion, N=81 790. REF = reference.

eTable 9. Sequential model adjustments for total physical activity (milligravity units) and risk of incident cancer in the UK Biobank among 38 078 male UK Biobank participants.

| | | Model 1 | Model 2 | Model 3 |
|----------------------------------|------------|----------------------|----------------------|----------------------|
| Cancer type | Case count | HR per 1 SD (95% CI) | HR per 1 SD (95% CI) | HR per 1 SD (95% CI) |
| Physical-activity-related cancer | 898 | 0.77 (0.71-0.84) | 0.80 (0.74-0.87) | 0.84 (0.78-0.91) |
| Bladder | 86 | 0.70 (0.54-0.92) | 0.72 (0.56-0.95) | 0.76 (0.58-1.00) |
| Breast | NA | NA | NA | NA |
| Colon | 207 | 0.77 (0.65-0.91) | 0.76 (0.64-0.90) | 0.80 (0.67-0.95) |
| Endometrial | NA | NA | NA | NA |
| Gastric cardia | 18 | 0.34 (0.17-0.67) | 0.41 (0.21-0.79) | 0.49 (0.25-0.98) |
| Head and neck | 68 | 0.86 (0.65-1.13) | 0.91 (0.69-1.18) | 0.88 (0.67-1.16) |
| Kidney | 83 | 0.85 (0.66-1.09) | 0.89 (0.69-1.13) | 0.90 (0.70-1.16) |
| Liver | 34 | 0.76 (0.50-1.15) | 0.77 (0.51-1.17) | 0.84 (0.55-1.29) |
| Lung | 148 | 0.54 (0.43-0.68) | 0.64 (0.52-0.80) | 0.68 (0.54-0.84) |
| Myeloid Leukaemia | 18 | 1.04 (0.63-1.72) | 1.11 (0.67-1.82) | 1.26 (0.76-2.10) |
| Myeloma | 61 | 0.92 (0.69-1.22) | 0.93 (0.70-1.24) | 0.94 (0.70-1.27) |
| Oesophageal adenocarcinoma | 56 | 0.83 (0.61-1.13) | 0.89 (0.66-1.20) | 1.01 (0.74-1.38) |
| Rectal | 121 | 0.95 (0.78-1.16) | 0.96 (0.79-1.17) | 0.98 (0.80-1.20) |
| Melanoma skin | 181 | 0.90 (0.77-1.07) | 0.88 (0.75-1.05) | 0.90 (0.76-1.08) |
| Non-Hodgkin lymphoma | 176 | 0.91 (0.77-1.08) | 0.90 (0.75-1.07) | 0.91 (0.76-1.09) |
| Pancreas | 80 | 0.84 (0.64-1.09) | 0.86 (0.66-1.11) | 0.93 (0.71-1.21) |
| Prostate | 1 380 | 1.05 (0.99-1.11) | 1.04 (0.98-1.10) | 1.03 (0.97-1.10) |

The standard deviation (SD) of physical activity was 8.3 milligravity unit in the main analytical sample. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. Models used age as the underlying time variable. Model 1: Unadjusted. Model 2: adjusted for ethnicity, smoking status, alcohol consumption, deprivation, and education. Model 3: Model 2 + adjusted for body mass index.

eTable 10. Sequential model adjustments for total physical activity (milligravity units) and risk of incident cancer in the UK Biobank among 48 478 female UK Biobank participants.

| | | Model 1 | Model 2 | Model 3 |
|----------------------------------|-----------------|----------------------|----------------------|----------------------|
| Cancer type | Case count | HR per 1 SD (95% CI) | HR per 1 SD (95% CI) | HR per 1 SD (95% CI) |
| Physical-activity-related cancer | 1 771 | 0.87 (0.83-0.92) | 0.88 (0.84-0.93) | 0.90 (0.86-0.95) |
| Bladder | 23 | 0.56 (0.33-0.94) | 0.54 (0.31-0.91) | 0.52 (0.30-0.90) |
| Breast | 995 | 0.90 (0.85-0.97) | 0.91 (0.85-0.97) | 0.91 (0.85-0.98) |
| Colon | 174 | 0.95 (0.80-1.12) | 0.94 (0.80-1.11) | 0.96 (0.81-1.14) |
| Endometrial | 153 | 0.76 (0.63-0.91) | 0.78 (0.65-0.93) | 0.89 (0.74-1.07) |
| Gastric cardia | <5 ^a | NA | NA | NA |
| Head and neck | 20 | 0.55 (0.32-0.96) | 0.61 (0.36-1.05) | 0.59 (0.34-1.04) |
| Kidney | 58 | 0.78 (0.58-1.06) | 0.82 (0.61-1.11) | 0.88 (0.64-1.19) |
| Liver | 26 | 0.48 (0.29-0.80) | 0.50 (0.30-0.84) | 0.55 (0.32-0.93) |
| Lung | 147 | 0.75 (0.62-0.91) | 0.86 (0.71-1.04) | 0.87 (0.72-1.06) |
| Myeloid Leukaemia | 25 | 0.89 (0.57-1.38) | 0.89 (0.57-1.39) | 0.90 (0.57-1.42) |
| Myeloma | 46 | 0.99 (0.72-1.36) | 1.01 (0.74-1.39) | 1.08 (0.79-1.49) |
| Oesophageal adenocarcinoma | 12 | 0.80 (0.41-1.55) | 0.89 (0.46-1.72) | 1.02 (0.51-2.01) |
| Rectal | 88 | 1.02 (0.82-1.27) | 1.02 (0.82-1.28) | 1.03 (0.82-1.29) |
| Melanoma skin | 147 | 0.92 (0.77-1.09) | 0.90 (0.75-1.08) | 0.90 (0.75-1.09) |
| Non-Hodgkin lymphoma | 140 | 0.80 (0.66-0.97) | 0.81 (0.67-0.98) | 0.82 (0.67-1.00) |
| Pancreas | 65 | 0.86 (0.65-1.14) | 0.88 (0.66-1.17) | 0.87 (0.65-1.17) |
| Prostate | NA | NA | NA | NA |

The standard deviation (SD) of physical activity was 8.3 milligravity unit in the main analytical sample. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. Models used age as the underlying time variable. Model 1: Unadjusted. Model 2: Adjusted for ethnicity, smoking status, alcohol consumption, deprivation, ever use of oral contraception, ever use of hormone replacement therapy, menopausal status, and parity. Model 2: Model 2 + adjusted for body mass index. Participants were limited to females without a history of hysterectomy for endometrial cancer, N=41 010. ^aUK Biobank policy states that tables should have a minimum number of 5 reported participants within a cell.

eTable 11. Sex-specific adjusted hazard ratios for median daily step count and physical-activity-related cancer risk in 38 078 male UK Biobank participants and 48 478 female UK Biobank participants.

| | Male | Female |
|---|--------------------|--------------------|
| Median daily steps | HR (95% CI) | HR (95% CI) |
| 3 000 | 1.42 (1.15 - 1.75) | 1.11 (0.93 - 1.33) |
| 5 000 (REF, ~10 th percentile) | 1.00 (1.00 - 1.00) | 1.00 (1.00 - 1.00) |
| 7 000 | 0.81 (0.72 - 0.91) | 0.92 (0.84 - 1.01) |
| 9 000 | 0.72 (0.61 - 0.85) | 0.87 (0.77 - 0.99) |
| 11 000 | 0.69 (0.57 - 0.82) | 0.86 (0.75 - 0.98) |
| 13 000 | 0.69 (0.57 - 0.84) | 0.82 (0.71 - 0.94) |
| 16 000 (~95 th percentile) | 0.65 (0.50 - 0.84) | 0.74 (0.61 - 0.90) |
| P value for linear trend | <0.001 | <0.001 |

Estimated hazard ratios (HR) and 95% confidence intervals (CI) were computed using a Cox proportional hazards model with restricted cubic spline functions. Observations were trimmed at the 1% and 99% of the distribution and 3 knots were placed at the 5th, 50th, and 95th percentile for the exposures in the main sample. The ~10th percentile was set as the referent group (5 000 steps). Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used attained age as the underlying time variable and were adjusted for ethnicity, smoking status, alcohol consumption, deprivation, and education. The overall model was further adjusted for sex and the female model was further adjusted for ever use of oral contraception, ever use of hormone replacement therapy, menopausal status, and parity. REF = reference.

eTable 12. Models for quintile of total physical activity (milligravity units), quintile of median daily step count, and risk of incident physical-activity-related cancer in UK Biobank participants who were never smokers (N=49 736).

| Quintile of physical activity | Total | Case count | HR (95% CI) |
|-------------------------------|-------|------------|------------------|
| Q1: <22.0 | 9 947 | 335 | REF |
| Q2: 22.0-25.7 | 9 946 | 269 | 0.83 (0.70-0.97) |
| Q3: 25.8-29.5 | 9 948 | 265 | 0.83 (0.71-0.98) |
| Q4: 29.6-34.5 | 9 947 | 244 | 0.80 (0.67-0.94) |
| Q5: 34.6+ | 9 948 | 195 | 0.68 (0.57-0.82) |
| P value for linear trend | | | <0.001 |
| Quintile of daily step count | Total | Case count | HR (95% CI) |
| Q1: <6 480 | 9 941 | 308 | REF |
| Q2: 6 480-8 318 | 9 953 | 281 | 0.93 (0.79-1.09) |
| Q3: 8 319-10 109 | 9 943 | 253 | 0.84 (0.71-0.99) |
| Q4: 10 110-12 469 | 9 951 | 255 | 0.85 (0.72-1.01) |
| Q5: 12, 470+ | 9 948 | 211 | 0.73 (0.61-0.87) |
| P value for linear trend | | | 0.001 |

Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. Models used age as the underlying time variable. Model was adjusted for sex, ethnicity, alcohol consumption, deprivation, and education. REF = reference.

eTable 13. Models for quintile of total physical activity (milligravity units), quintile of median daily step count, and risk of incident physical-activity-related cancer in 86 556 UK Biobank participants before and after removing the first two years of follow-up (N=83 435).

| Quintile of physical activity | Total | Case count | HR (95% CI) |
|--|--|---------------------------------|---|
| Q1: <21.7 | 16 687 | 480 | REF |
| Q2: 21.7-25.4 | 16 687 | 374 | 0.83 (0.72-0.95) |
| Q3: 25.5-29.2 | 16 687 | 367 | 0.84 (0.73-0.96) |
| Q4: 29.3-34.3 | 16 687 | 320 | 0.77 (0.67-0.89) |
| Q5: 34.4+ | 16 687 | 280 | 0.73 (0.63-0.85) |
| P value for linear trend | | | 0.001 |
| Quintile of daily step count | Total | Case count | HR (95% CI) |
| | | | |
| Q1: < 6 343 | 16 687 | 456 | REF |
| Q1: < 6 343 Q2: 6 343-8 205 | 16 687 16 683 | 456 371 | REF 0.85 (0.74-0.98) |
| Q1: < 6 343 Q2: 6 343-8 205 Q3: 8 206-10 021 | 16 687 16 683 16 689 | 456 371 353 | REF 0.85 (0.74-0.98) 0.83 (0.72-0.95) |
| Q1: < 6 343 Q2: 6 343-8 205 Q3: 8 206-10 021 Q4: 10 022-12 433 | 16 687 16 683 16 689 16 682 | 456 371 353 333 | REF 0.85 (0.74-0.98) 0.83 (0.72-0.95) 0.79 (0.69-0.91) |
| Q1: < 6 343 Q2: 6 343-8 205 Q3: 8 206-10 021 Q4: 10 022-12 433 Q5: 12 434+ | 16 687 16 683 16 689 16 682 16 694 | 456 371 353 333 308 | REF 0.85 (0.74-0.98) 0.83 (0.72-0.95) 0.79 (0.69-0.91) 0.76 (0.66-0.88) |

Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. Physical-activity-related cancer was defined as 13 site specific cancers (oesophageal adenocarcinoma, liver, lung, kidney, gastric cardia, endometrial, myeloid leukaemia, myeloma, colon, head and neck, rectal, bladder, and breast). Models used age as the underlying time variable. Model was adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. REF = reference.

eFigure 1. Participant flow diagram for the analysis of daily physical activity and step count measured by accelerometers in UK Biobank participants.



eFigure 2. Hazard Ratios reallocating time to a given movement behaviour from all other behaviours proportionally and incident physical-activity-related cancer in 86 556 UK Biobank participants.



Hazard ratios (HR) and 95% confidence intervals (CI) for incident physical-activity-related cancer associated with reallocating time to from one behaviour to another behaviour proportionally. Models are based on 2 669 events in 86 556 participants. Hazard ratios are relative to the mean behaviour composition (8.1 hours/day sleep, 10.5 hours/day sedentary behaviour (SB), 4.9 hours/day light intensity physical activity behaviours (LIPA), 0.46 hours/day (27.4 minutes/day) moderate-vigorous intensity physical (MVPA) activity behaviours). Models used attained age as the underlying time variable and were adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Models are based on 2 669 events in 86 556 participants.

eFigure 3. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after adjusting for body mass index as a sensitivity analysis.



Hazard ratios are relative to the mean behaviour composition (8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours, 0.46 hours/day (27.4 minutes/day) moderate-vigorous intensity physical activity behaviours). Models used attained age as the underlying time variable and were adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Models are based on 2 669 events in 86 556 participants. SB = sedentary behaviour, LIPA = light intensity activity, MVPA = moderate-vigorous intensity activity, hr = hour.

eFigure 4. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after adjusting for dietary factors as a sensitivity analysis.



Hazard ratios are relative to the mean behaviour composition (8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours, 0.46 hours/day (27.4 minutes/day) moderate-vigorous intensity physical activity behaviours). Models used attained age as the underlying time variable and were adjusted for sex, ethnicity, smoking status, alcohol consumption, deprivation, and education. Models are based on 2 669 events in 86 556 participants. SB = sedentary behaviour, LIPA = light intensity activity, MVPA = moderate-vigorous intensity activity, hr = hour.

eFigure 5. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model among 48 478 female participants (blue) and 38 078 male participants (red).



Hazard ratios are relative to the mean behaviour composition in each sex (female – 8.2 hours/day sleep, 10.1 hours/day sedentary behaviour, 5.3 hours/day light intensity physical activity behaviours, 0.38 hours/day (22.8 minutes/day) moderate-vigorous intensity physical activity behaviours; male – 7.9 hours/day sleep, 11.0 hours/day sedentary behaviour, 4.5 hours/day light intensity behaviours, 0.58 hours/day (35.0 minutes/day) moderate-vigorous intensity physical activity behaviours). Models used attained age as the underlying time variable and were adjusted for ethnicity, smoking status, alcohol consumption, deprivation, and education. Female models were further adjusted for ever use of oral contraception, ever use of hormone replacement therapy, menopausal status, and parity Model is based on 1 771 events in 48 478 female participants and 898 events in 38 078 male participants. SB = sedentary behaviour, LIPA = light intensity activity, MVPA = moderate-vigorous intensity activity, hr = hour.

eFigure 6. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after restricting to never smokers (red, N=49 736).



Hazard ratios are relative to the mean behaviour composition in each sample (full sample – 8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours; Non-smoking subgroup – 8.1 hours/day sleep, 10.4 hours/day sedentary behaviour, 5.0 hours/day light intensity physical activity behaviours, 0.48 hours/day (28.7 minutes/day) moderate-vigorous intensity physical activity behaviours; Non-smoking subgroup – 8.1 hours/day sleep, 10.4 hours/day sedentary behaviour, 5.0 hours/day light intensity physical activity behaviours, 0.48 hours/day (28.7 minutes/day) moderate-vigorous intensity physical activity behaviours). Models used attained age as the underlying time variable and were adjusted for ethnicity, smoking status, alcohol consumption, deprivation, and education. The main model is based on 2 669 events in 86 556 participants and the sensitivity analysis model is based on 1 308 events in 49 736 participants. SB = sedentary behaviour, LIPA = light intensity activity, MVPA = moderate-vigorous intensity activity, hr = hour.

eFigure 7. Hazard ratios for all behaviour pairs and incident physical-activity-related cancer risk for estimated using a multivariable-adjusted Cox regression model in 86 556 UK Biobank participants before (blue) and after removing the first two years of follow-up (red, N=83 435).



Hazard ratios are relative to the mean behaviour composition in each sample (full sample – 8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours; sample with at least 2-years follow-up – 8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours; sample with at least 2-years follow-up – 8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours; sample with at least 2-years follow-up – 8.1 hours/day sleep, 10.5 hours/day sedentary behaviour, 4.9 hours/day light intensity physical activity behaviours, 0.46 hours/day (27.6 minutes/day) moderate-vigorous intensity physical activity behaviours). Models used attained age as the underlying time variable and were adjusted for ethnicity, smoking status, alcohol consumption, deprivation, and education. The main model is based on 2 669 events in 86 556 participants and the sensitivity analysis model is based on 1 821 events in 83 435 participants. SB = sedentary behaviour, LIPA = light intensity activity, MVPA = moderate-vigorous intensity activity, hr = hour.